Unlock instant, AI-driven research and patent intelligence for your innovation.

Canine lyme disease vaccine

A vaccine, alpha virus technology, applied in the field of canine Lyme disease vaccine, can solve the problem of no report

Pending Publication Date: 2020-07-17
INTERVET INT BV
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, Gipson et al. [Vaccine.21(25-26):3875-84.(2003)] have used the RP platform to encode the OpsA antigen in vaccination trials in mouse models, but no similar studies have been reported in dogs. test
[0014] Therefore, although Lyme vaccines offer enhanced effectiveness, and there have been many speculated dead ends and / or failures in the past, but there remains a long-felt need for further improved Lyme disease vaccines to better protect mammals, especially dogs, from The attack of this debilitating disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Canine lyme disease vaccine
  • Canine lyme disease vaccine
  • Canine lyme disease vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] Construction of OspA and OspC vaccines delivered by alphavirus RNA replicon particles

[0078] RNA viruses have been used as vector-vehicles for the introduction of vaccine antigens that have been genetically engineered into their genomes. However, to date, their use has been largely limited to the incorporation of viral antigens into RNA viruses, followed by introduction of the virus into recipient hosts. The result is the induction of protective antibodies against the incorporated viral antigens. For example, alphavirus replicon vectors have been used to express the C. botulinum neurotoxin H C or B. anthracis protective antigen to protect mice from botulinum neurotoxin and anthrax [Lee et al., Vaccine24(47-48) 6886-6892(2006)]. Alphavirus RNA replicon particles have been used to encode pathogenic antigens. Such alphavirus replicon platforms have been developed by several different alphaviruses, including Venezuelan equine encephalitis virus (VEE) [Pushko et al., Vi...

Embodiment 2

[0084] Vaccines with RP-OspA constructs

[0085] Materials and methods

[0086] Constructs: RP-OspA constructs were generated as described above using the nucleotide sequence encoding an antigen comprising an immunogenic epitope of outer surface protein A.

[0087] Animals: 5-month-old Beagle dogs (Marshall Bioresources) were housed together in a kennel, with free access to food and water.

[0088] Preparation of RP-OspA vaccine: OspA RNA was electroporated into Vero cells together with helper RNA. After the co-electroporation process, OspA was packaged into RP, resulting in RP-OspA. Then, RP-OspA was mixed with stabilizers (sucrose, N-Z amine, gelatin), 0.9% saline, amphotericin B, and gentamicin so that a 1.0 mL dose contained a target concentration of 1.0×10 8 replicon particles / mL. Afterwards, the vaccine is lyophilized.

[0089] Vaccination and serum collection: Dogs were vaccinated subcutaneously in the neck of the dog with a 1 mL dose of RP-OspA vaccine, and booste...

Embodiment 3

[0099] Vaccines with RP-OspC constructs

[0100] Materials and methods

[0101] Constructs: RP-OspC constructs were generated as described above using the nucleotide sequence encoding an antigen comprising an immunogenic epitope of outer surface protein C.

[0102] Animals: 5-month-old Beagle dogs (Marshall Bioresources) were housed together in a kennel, with free access to food and water.

[0103] Preparation of RP-OspC vaccine: OspC RNA was electroporated into Vero cells together with helper RNA. After the co-electroporation process, OspC was packaged into RP, resulting in RP-OspC. Then, RP-OspC was mixed with stabilizers (sucrose, N-Z amine, gelatin), 0.9% saline, amphotericin B, and gentamicin so that a 1.0 mL dose contained a target concentration of 1.0×10 8 replicon particles / mL. Afterwards, the vaccine is lyophilized.

[0104] Vaccination and serum collection: Dogs were vaccinated subcutaneously in the neck of the dog with a 1 mL dose of RP-OspC vaccine, and booste...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.

Description

[0001] Cross References to Related Applications [0002] This application claims priority under 35 U.S.C. §119(c) to U.S. Provisional Application Serial No. 62 / 594,342, filed December 04, 2017. technical field [0003] The present invention relates to new vaccines for canine Lyme disease. Also provided are methods of making and using the vaccines alone or in combination with other protective agents. Background technique [0004] Canine Lyme disease is caused by infection with spirochetes of the Borrelia genus species (spp.), mainly including B. burgdorferi sensus (ss) in the United States and B. burgdorferi ss, B. garinii, and B. afzelii in Europe[ Baranton et al., Int. J. Sys. Bacteriol. 42:378-383 (1992); Hovius et al., J. Clin. Microbiol. 38:2611-2621 (2000)]. Spirochetes are transmitted by blood-feeding infected ticks of the genus Ixodess pp., and infection causes clinical signs in dogs ranging from subsynovitis to acute arthritis and arthralgia [Jacobson et al., Semin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/193A61K9/10A61P31/16A61P31/12A61K39/00A61K39/02C07K14/20A61P31/00
CPCA61K39/0225A61K39/193C07K14/20A61K2039/5256A61K2039/53A61K2039/552A61K2039/70C07K2319/00A61P31/00Y02A50/30A61P31/04A61K39/0241A61K2039/545
Inventor R·L·拉弗勒J·C·丹特M·A·莫勒S·M·卡利斯特许志昌
Owner INTERVET INT BV